Literature DB >> 29064062

Assessing robustness of designs for random effects parameters for nonlinear mixed-effects models.

Stephen B Duffull1, Andrew C Hooker2.   

Abstract

Optimal designs for nonlinear models are dependent on the choice of parameter values. Various methods have been proposed to provide designs that are robust to uncertainty in the prior choice of parameter values. These methods are generally based on estimating the expectation of the determinant (or a transformation of the determinant) of the information matrix over the prior distribution of the parameter values. For high dimensional models this can be computationally challenging. For nonlinear mixed-effects models the question arises as to the importance of accounting for uncertainty in the prior value of the variances of the random effects parameters. In this work we explore the influence of the variance of the random effects parameters on the optimal design. We find that the method for approximating the expectation and variance of the likelihood is of potential importance for considering the influence of random effects. The most common approximation to the likelihood, based on a first-order Taylor series approximation, yields designs that are relatively insensitive to the prior value of the variance of the random effects parameters and under these conditions it appears to be sufficient to consider uncertainty on the fixed-effects parameters only.

Keywords:  Nonlinear mixed-effects models; Optimal design; Random effects; Robust designs

Mesh:

Year:  2017        PMID: 29064062     DOI: 10.1007/s10928-017-9552-y

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  13 in total

1.  Further developments of the Fisher information matrix in nonlinear mixed effects models with evaluation in population pharmacokinetics.

Authors:  Sylvie Retout; France Mentré
Journal:  J Biopharm Stat       Date:  2003-05       Impact factor: 1.051

2.  POPED, a software for optimal experiment design in population kinetics.

Authors:  Marco Foracchia; Andrew Hooker; Paolo Vicini; Alfredo Ruggeri
Journal:  Comput Methods Programs Biomed       Date:  2004-04       Impact factor: 5.428

3.  Adaptive optimal design for bridging studies with an application to population pharmacokinetic studies.

Authors:  Lee Kien Foo; Stephen Duffull
Journal:  Pharm Res       Date:  2012-02-14       Impact factor: 4.200

4.  Methods of robust design of nonlinear models with an application to pharmacokinetics.

Authors:  Lee-Kien Foo; Stephen Duffull
Journal:  J Biopharm Stat       Date:  2010-07       Impact factor: 1.051

5.  Methods and software tools for design evaluation in population pharmacokinetics-pharmacodynamics studies.

Authors:  Joakim Nyberg; Caroline Bazzoli; Kay Ogungbenro; Alexander Aliev; Sergei Leonov; Stephen Duffull; Andrew C Hooker; France Mentré
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

6.  Robust population pharmacokinetic experiment design.

Authors:  Michael G Dodds; Andrew C Hooker; Paolo Vicini
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-02       Impact factor: 2.745

7.  Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments.

Authors:  D Z D'Argenio
Journal:  Math Biosci       Date:  1990-04       Impact factor: 2.144

8.  Influence of covariance between random effects in design for nonlinear mixed-effect models with an illustration in pediatric pharmacokinetics.

Authors:  Cyrielle Dumont; Marylore Chenel; France Mentré
Journal:  J Biopharm Stat       Date:  2014       Impact factor: 1.051

9.  Current Use and Developments Needed for Optimal Design in Pharmacometrics: A Study Performed Among DDMoRe's European Federation of Pharmaceutical Industries and Associations Members.

Authors:  F Mentré; M Chenel; E Comets; J Grevel; A Hooker; M O Karlsson; M Lavielle; I Gueorguieva
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-06-05

10.  The effect of Fisher information matrix approximation methods in population optimal design calculations.

Authors:  Eric A Strömberg; Joakim Nyberg; Andrew C Hooker
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-11-01       Impact factor: 2.745

View more
  1 in total

1.  Tutorial for $DESIGN in NONMEM: Clinical trial evaluation and optimization.

Authors:  Robert J Bauer; Andrew C Hooker; France Mentre
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-10-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.